New hope for elderly kidney cancer patients: cabozantinib under review
NCT ID NCT04416646
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how safe and effective the drug Cabozantinib is for people aged 70 and older with advanced kidney cancer. Researchers tracked side effects and tumor response in 100 participants. The goal was to see if this treatment works well in older patients who have already tried other therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Istituto Oncologico Veneto
Padova, Italy, 35100, Italy